- Rallybio press release ( NASDAQ: RLYB ): Q3 GAAP EPS of -$0.60 misses by $0.06 .
- Cash and cash equivalents of $132.420.
For further details see:
Rallybio GAAP EPS of -$0.60 misses by $0.06For further details see:
Rallybio GAAP EPS of -$0.60 misses by $0.06Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Jonathan Lieber, Chief Financial Officer of Rallybio, will present a corporate overview at th...
– First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries – – Topline Results Suggest a Significant Increase in the Number of Pregnancies at Higher Risk for FNAIT Annually and the RLYB212 Addressable Market – ...